A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Exclusion Criteria

• •Have symptomatic or untreated central nervous system (CNS) metastases.
• •Have an established diagnosis of uncontrolled diabetes mellitus.
• •Have a history of, or current evidence of, a clinically significant cardiac condition or QT/QTcF-related conditions.
• •Have another etiology for nausea and vomiting, or receives medications with know or potential antiemetic activity
• •Signs, symptoms or history of thyroid tumors
• •Receives treatment with a gastric inhibitory polypetide (GIP) or glucagon-like peptide-1 (GLP-1) receptor agonist within 4 weeks prior to chemotherapy.
• •Have participated in a clinical study involving study intervention within 30 days of Cycle 1 Day 1 (C1D1). If the previous study intervention has a long half-life, within 3 months or 5 halflives, whichever is longer, of C1D1.
• •Are pregnant, breastfeeding, or intend to become pregnant during the study or within 30 days of the last dose of study intervention.